度普利尤单抗治疗儿童特应性皮炎的临床与分子改善:TREATKids登记分析
基于前瞻性TREATkids登记,观察接受度普利尤单抗治疗的儿童和青少年特应性皮炎患者,评估临床评分、蛋白质组和皮肤微生物组变化。治疗3个月时EASI 50/75/90应答率分别为87%、60%、30%,无停药,结膜炎发生率4.0%;病变皮肤161个失调蛋白中144个下调,金黄色葡萄球菌过度生长和α多样性降低趋于正常化。
要点
- 度普利尤单抗治疗3个月时EASI 50/75/90应答率分别为87%、60%、30%。
- 治疗3个月时病变皮肤161个失调蛋白中144个下调,包括CCL17/TARC、CXCL8、IL-6等。
- 基线皮肤菌群失调(金黄色葡萄球菌过度生长、α多样性降低)在治疗3个月后趋于正常化。
核心结论
- 度普利尤单抗与儿童特应性皮炎患者快速、持续的临床和分子改善相关。
研究设计与样本
- 前瞻性TREATkids登记中的观察性分析,纳入常规诊疗中接受度普利尤单抗治疗的儿童和青少年。
- 基线数据来自200例患者,随访数据来自124例患者;部分亚组进行皮肤胶带条蛋白质组学(Olink Explore Inflammation 384,n=20)和16S rRNA基因测序(n=48)。
主要发现
- 治疗开始时疾病负担高:平均EASI=16.5,objective SCORAD=44.9,峰值瘙痒NRS=6.6。
- 第3个月EASI 50、75、90应答率分别为87%、60%、30%;第6和第12个月应答率与第3个月基本一致。
- 无停药,结膜炎发生率为4.0%。
- 蛋白质组分析显示基线病变皮肤中警报素、Th2趋化因子和组织重塑标志物显著上调,第3个月时161个失调蛋白中144个下调,包括CCL17/TARC、CXCL8、IL-6、IL-18和基质金属蛋白酶。
- 微生物组分析显示基线菌群失调伴金黄色葡萄球菌过度生长和α多样性降低,治疗3个月后趋于非病变样状态。
临床怎么用
- 度普利尤单抗在儿童特应性皮炎中显示快速且持续的临床改善,结膜炎发生率较低。
- 治疗可下调Th2相关趋化因子和炎症蛋白,并改善皮肤菌群失调。
局限性
- 观察性分析,样本量有限(基线200例,随访124例),蛋白质组和微生物组亚组样本量较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Real-world evidence on clinical and molecular outcomes of systemic therapy for pediatric atopic dermatitis remains limited. Within the prospective TREATkids registry, we conducted an observational analysis of children and adolescents treated with dupilumab in routine care. Baseline data from 200 and follow-up data from 124 patients were evaluated for clinician- and patient-/caregiver-reported outcomes, alongside epidermal proteomic profiling using tape strips and the Olink Explore Inflammation 384 (n = 20) panel and 16S ribosomal RNA gene sequencing for skin microbiome assessment in subsets (n = 48). At treatment initiation, disease burden was high (mean Eczema Area and Severity Index = 16.5, objective SCORing Atopic Dermatitis = 44.9, peak pruritus numerical rating scale = 6.6). By month 3, Eczema Area and Severity Index 50, 75, and 90 response rates were 87, 60, and 30%. Response rates at months 6 and 12 were generally consistent with those observed at month 3, with no discontinuations and conjunctivitis occurring in 4.0%. Proteomic analyses demonstrated marked baseline upregulation of alarmins, T helper 2 chemokines, and tissue-remodeling markers in lesional skin, followed by downregulation of 144/161 dysregulated proteins at month 3, including CCL17/TARC, CXCL8, IL-6, IL-18, and matrix metalloproteinases. Microbiome profiling showed baseline dysbiosis with Staphylococcus aureus overabundance and reduced α-diversity, normalizing toward a nonlesional-like state after therapy at month 3. Overall, dupilumab was associated with rapid, sustained clinical and molecular improvement.
引用
- Fonfara M, Stölzl D, Hartmann J, et al. Clinical and molecular improvements in pediatric patients with atopic dermatitis treated with dupilumab: An analysis from the TREATKids registry. J Invest Dermatol. 2026. PMID: 42413573. doi:10.1016/j.jid.2026.06.1283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。